Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (K��hdorf Katja) .

91 - 100 / 184
First pagePrevious page6789101112131415Next pageLast page
91.
Programske smernice DORA
Mateja Kurir-Borovčić, Katja Jarm, Kristijana Hertl, Veronika Kutnar, 2021, published scientific conference contribution

Keywords: epidemija, presejalni programi, rak dojke, javno zdravstvo
Published in DiRROS: 16.03.2022; Views: 556; Downloads: 267
.pdf Full text (771,09 KB)
This document has many files! More...

92.
93.
Prehrana za bolnike s težavami pri požiranju - disfagijo
Eva Peklaj, Brigita Avramović Brumen, 2021, not set

Keywords: požiranje, motnje, prehranska podpora, nasveti
Published in DiRROS: 16.11.2021; Views: 810; Downloads: 280
.pdf Full text (2,12 MB)

94.
95.
Ectomycorrhiza between Scleroderma Areolatum Ehrenb. and Fagus sylvatica L.
Tanja Mrak, Katja Kühdorf, Tine Grebenc, Ines Štraus, Marko Bajc, Nada Žnidaršič, Babette Münzenberger, Hojka Kraigher, 2015, published scientific conference contribution abstract

Published in DiRROS: 03.11.2021; Views: 737; Downloads: 254
.pdf Full text (1,05 MB)

96.
Poročilo 2020 o izvajanju letnega programa dela javnih služb v oljkarstvu
Maja Podgornik, Viljanka Vesel, Dunja Bandelj, Bojan Butinar, Elizabeta Bonin, Janko Brajnik, Erika Bešter, Jakob Fantinič, Katja Fičur, Vasja Juretič, Matjaž Prinčič, Vasilij Valenčič, Saša Volk, Milena Bučar-Miklavčič, 2021, other monographs and other completed works

Abstract: V okviru javne službe za izvajanje strokovnih nalog v oljkarstvu, so bile v letu 2020 izvedene naloge: selekcija, introdukcija, razmnoževanje sadilnega material, ugotavljanje ustreznih tehnologije za pridelavo oljk ter ugotavljanje vrednosti oljk za predelavo. V poročilu so zbrane morfološke in agronomske lastnosti ter značilnosti oljčnega olja sort 'Buga', 'Črnica' in 'Drobnica', Maurino, Arbequina, Leccione, Itrana, Leccio del corno in 'Štorta' za opazovanja v letu 2019. Predstavljeni so tudi rezultati genotipizacije izbranih sort ter agronomskega vrednotenja in fenofaze različnih sort, ki so zasajene v introdukcijsko-kolekcijskem nasadu Purissima in Šempeter. V poročilu so zbrani podatki tehnoloških poskusov pridelave in predelave; parametri, ki karakterizirajo posamezna sortna olja ter parametri kakovosti oljčnega olja letnika 2020.%Ključne besede: oljkarstvo, oljka, oljčno olje, tehnologija pridelave, ocena letnika, introdukcija, selekcija
Keywords: elektronske knjige
Published in DiRROS: 09.07.2021; Views: 1015; Downloads: 496
.pdf Full text (8,11 MB)
This document has many files! More...

97.
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program
Oliver Illini, Maximilian J Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M. S. Hashemi, Florian Huemer, Anders Vikström, Katja Mohorčič, 2021, original scientific article

Abstract: Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusio-%positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naïve, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n=8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade >/=3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.
Keywords: non-small cell lung carcinoma -- drug therapy -- genetics, molecular targeted therapy, real-world data, selpercatinib, targeted therapy, tyrosine kinase inhibitor
Published in DiRROS: 16.06.2021; Views: 1248; Downloads: 703
.pdf Full text (777,25 KB)
This document has many files! More...

98.
99.
Usefulness of rapid antigen testing for SARS-CoV-2 screening of healthcare workers : ǂa ǂpilot study
Anja Šterbenc, Viktorija Tomič, Urška Bidovec, Katja Vrankar, Aleš Rozman, Mihaela Zidarn, 2021, short scientific article

Abstract: Background. Identification of infected healthcare workers (HCWs) is an important step in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission control. Rapid antigen tests (RATs) are considered an important addition to molecular tests in diagnosing coronavirus disease 2019 (COVID-19), mainly because of their fast turnaround time, easier analytical procedure and lower price. However, real-life studies on the usefulness of such testing for screening of HCWs are limited. Methods. Physicians, nurses and hospital attendants currently working at the University Clinic of Respiratory and Allergic Diseases Golnik were invited to participate in the pilot study. Nasopharyngeal swabs were obtained three times per week for two consecutive weeks and tested with a point-of-care RAT and reverse transcription polymerase chain reaction (RT-PCR). Serum samples were obtained at the beginning of the study and 2 weeks after the last swab was collected to evaluate the serological status. Results. A total of 191 nasopharyngeal swabs from 36 HCWs were obtained. None of the samples tested was positive for the presence of SARS-CoV-2 antigen, whereas two HCWs tested positive on RT-PCR. Of these, one HCW had a newly identified SARS-CoV-2 infection, whereas RT-PCR probably detected a previous but recent infection in the other HCW. Conclusio.n Based on the results of this pilot study, it is unlikely that RAT will reliably detect novel SARS-CoV-2 infections among asymptomatic HCWs despite serial sampling. Although RT-PCR-based screening of HCWs may not be feasible due to high sample volume, molecular methods may identify SARS-CoV-2-infected HCWs already during the presymptomatic stage.
Keywords: SARS-CoV-2, health personnel, COVID-19 serological testing, real-time polymerase chain reaction, rapid antigen test, screening
Published in DiRROS: 28.05.2021; Views: 1022; Downloads: 304
URL Link to file

100.
Search done in 0.35 sec.
Back to top